secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2023-06-02T23:59:59+00:00
Accession:  0000950170-23-026086
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stockholders approve amendment increasing share reserve by 4.05M shares
-----------------------------------------------------------------------

- At May 31 annual meeting, stockholders approved Amended 2014 Plan increasing authorized shares by 4,050,000.
- Diane Parks and Mary T. Szela elected as Class III directors until 2026 annual meeting.
- Ernst & Young LLP ratified as independent auditor for fiscal year ending Dec 31, 2023.
- Advisory vote on executive compensation approved with ~52M for vs ~0.88M against.
- Amended 2014 Plan approved with ~46.8M for, ~5.9M against, ~1.4M abstain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000095017023026086/0000950170-23-026086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000095017023026086/kura-20230531.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-026086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer